Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25604363 | 0.87 | PRMT3 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24744949 | 0.85 | MEN1 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL9493744 | 0.83 | MEN1 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24912449 | 0.83 | PRMT3 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13996765 | 0.81 | MEN1 (0.40) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL5932747 | 0.79 | MEN1 (0.48) | MEN1KMT2AALDH1A1SIGMAR1BCHE | |
| SCHEMBL26350120 | 0.78 | PRMT3 (0.34) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25633209 | 0.77 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25594688 | 0.75 | MEN1 (0.36) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24693233 | 0.75 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| US-5530127-A | AMINATION OF PRIMARY OR SECONDARY ALCOHOL IN PRESENCE OF ZIRCONIUM/COPPER/NICKEL OXIDE CATALYST, ALSO CONTAINING MOLYBDENUM AND POSSIBLE ALUMINUM AND MANGANESE | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0696572-A1 | Process for the preparation of amines | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-14 | — | — | EP | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
| US-5348953-A | Elastase inhibitor | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| WO-1994013636-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5236956-A | Compounds for the treatment of urinary incontinence | KABI PHARMACIA AKTIEBOLAG (SE) | 1993-08-17 | — | — | US | disclosed |
| EP-0367040-B1 | COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE | Kabi Pharmacia AB (SE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0525973-A2 | Substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1993000332-A1 | SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| EP-0367040-A1 | Compounds for the treatment of urinary incontinence | Kabi Pharmacia AB (SE) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | PRMT3 1423/4885CARM1 1354/4885PRMT6 1310/4885 |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | PRMT3 3661/4885CARM1 3175/4885PRMT6 3462/4885 |
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | AGT, AGTR1, AGTR2 | PRMT3 2957/4885CARM1 4661/4885PRMT6 2771/4885 |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | PRMT3 3962/4885CARM1 2458/4885PRMT6 2727/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | PRMT3 4181/4885CARM1 3499/4885PRMT6 4452/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | PRMT3 3361/4885CARM1 4741/4885PRMT6 2671/4885 |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | BCAT1, BCAT2, SNRPE | PRMT3 1882/4885CARM1 2364/4885PRMT6 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.